Objective: To evaluate the efficacy of treatment with monosialotetrahexosyl ganglioside(GM1) combined with mouse nerve growth factor(NGF) on early stage of treatment and short-term prognosis of acute Bell’s palsy. Methods: A retrospective study was conducted to analyze clinical data of 219 patients with Bell’s palsy from January 2009 to December 2015. The patients with acute Bell’s palsy were divided into four groups, including the GM1 combined with NGF group(58 cases), the GM1 group(55 cases), the NGF group(51 cases), and the basic group(without any special neurotrophic drugs, 55 cases). All cases had the same basic treatment. We used the House-Brackmann facial nerve grading system(HB) and the Sunnybrook grading system to evaluate the efficacy of treatment before starting treatment, after 1 week and 2 weeks of treatment and 1 month after onset. Results: There was greater improvement in the mean HB and Sunnybrook scores of the GM1 combined with NGF group in comparison to the other three groups at 2 weeks and 4 weeks(P<0.01). After 4 weeks, 91.4% patients had good recovery in the GM1 combined with NGF group compared with the other three groups(P<0.01), the recovery rates of the GM1 group, NGF group and basic group at the same time point were 74.5%, 78.4% and 50.9%, respectively. Conclusion: The combination of GM1 and NGF treatment increases the possibility of recovery in acute Bell’s palsy.